No phaseActive, not recruiting
An Efficacy and Safety Study of Akkermansia Muciniphila AKM Lab-01 in Hypercholesterolaemia
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Preliminary Efficacy of Akkermansia Muciniphila AKM Lab-01 in Subjects With Hypercholesterlemia
- Sponsor
- Moon (Guangzhou) Biotechnology Co., Ltd. (Industry)
- Enrolment
- 60 planned
- Conditions
- Hypercholesterolaemia
- Interventions
- Probiotic; Placebo
- Ages
- adults, older adults
- Registry
- NCT06974266
Full record on ClinicalTrials.gov
From the registry
The purpose of this study was to assess the safety and efficacy of AKM Lab-01 in subjects with hypercholesterolemia. This study will be conducted as a randomized, double-blind, placebo-controlled trial, eligible hypercholesterolemic participants were administered daily oral doses of either AKM Lab-01 or a placebo. Baseline clinical parameters, blood samples, and stool specimens were collected before and after the intervention for comparative analysis.
Primary outcomes
- Changes in TC and LDL-C
- AE and SAE
History
Study completion expected
Primary completion expected
Last registry update
Started
Registered